Research programme: non-alcoholic steatohepatitis therapeutics - 89bio
Latest Information Update: 28 Nov 2022
At a glance
- Originator Teva Pharmaceutical Industries
- Developer 89bio
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Israel
- 01 Nov 2018 89bio acquires biologic and small molecule drug candidates from Teva Pharmaceutical Industries
- 25 Oct 2018 Preclinical trials in Non-alcoholic steatohepatitis in Israel (unspecified route)